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Introduction
The incidence of malignant melanoma shows a constant increase, particularly in the Caucasian population, worldwide during the past decades (Holmes, 2014; Nikolaou and Stratigos, 2014) . The major risk factors are exposure to ultraviolet radiation, high nevus counts, large nevus size, and genetic predisposition (Marks, 2000; Rosendahl et al., 2015) . Although the mechanism of transformation is incompletely characterized, histological examinations have demonstrated that melanocytic nevi precursors can be identified in between 26 and 58% of cutaneous melanomas (Sagebiel, 1993; Tsao et al., 2003) .
The origin and developmental process of nevi is not yet fully defined, although recent data support a dermal origin (Grichnik et al., 2014) . Nevi demonstrate progressive changes in histological appearance throughout life (Lund and Stobbe, 1949) , which could be referred to as
Significance
The development and progression of a melanocytic nevus into a malignant melanoma is characterized by alteration of gene expression and growth-promoting signaling to break the growth-arrested state. By combining the gene expression profiles from skin lesions and cell culture models, we identify candidate biomarkers that distinguish malignant melanoma from benign melanocytic lesions. Tubulin b-3 expression may have a diagnostic impact in melanoma.
maturation. Eventually intra-epidermal proliferation of the melanocytes will cease. The nevus becomes entirely intradermal with reduced proliferative activity and finally undergoes progressive involution. Importantly, the features that are believed to distinguish benign nevi from melanoma are noted within the senescence pathways that signal growth arrests (Ross et al., 2011) . Cellular senescence can be triggered by extensive loss of telomeric sequences due to replicative shortening (d'Adda di Fagagna et al., 2003) or by constitutive activation of oncogenes or loss of tumor suppressors (Courtois-Cox et al., 2008; Serrano et al., 1997) . The cellular senescent state is controlled by multiple mechanisms, including global chromatin and epigenetic modification, DNA damage response, and alteration of secretory pathways and autophagy (Campisi, 2013) . Several molecular effectors of senescence have been identified, such as the tumor suppressors p53, p16 INK4a , and Rb (Michaloglou et al., 2005) . Melanomas and nevi share growth-promoting mutations, for example, in BRAF or NRAS, implying that nevi are growth-arrested by the activation of oncogene-induced senescence pathways (Ross et al., 2011; Souroullas and Sharpless, 2015) . In nevi harboring the most common BRAF mutation, V600E, the induction of both p16
INK4a and senescence-associated acidic b-galactosidase (b-Gal) activity can be demonstrated (Michaloglou et al., 2005) . Noteworthy, telomere shortening has also been observed in melanocytic nevi, indicating that the growth arrest might be induced by mixed mechanisms (Bandyopadhyay et al., 2001) . Taken together, these observations suggest that nevi are mainly growth-restricted by the senescence machinery as a defense mechanism against malignant transformation.
Histopathological examination is the gold standard for diagnosing melanocytic neoplasms. Despite well-defined criteria for diagnosis and classification, the differentiation between melanocytic nevi and melanomas is challenging and controversial in many cases due to overlapping morphologic features. As presented in several comparative studies, the diagnoses of certain melanocytic tumors show variability and discordance between experienced pathologists (Farmer et al., 1996; Lodha et al., 2008) . Immunohistochemistry-based molecular markers are routinely assessed for different cancers; however, none of the protein-based studies in primary melanoma have advanced into clinical practice (Weiss et al., 2015) . Given the clinical and histopathological heterogeneity of primary melanomas, new protein markers are needed to better identify patients at risk to develop an advanced disease.
In this study, we constructed a cellular model system of melanocyte senescence, performed a microarray analysis, and combined these results with the gene expression arrays analyses extracted from a public database of nevi and malignant melanomas. Novel protein biomarkers that could distinguish senescent cells from proliferating were identified and the clinical applicability of tubulin b-3 was tested.
Results
Identification of differentially expressed genes in young and senescent melanocyte cultures Human melanocytes were cultured and samples withdrawn after 3 days (young melanocytes) and after a minimum of 30 days (senescent melanocytes) when the cells had stopped dividing. Senescent melanocytes were identified as enlarged cells with flattened morphology and positive b-Gal staining ( Figure 1A ). b-Gal activity was increased ( Figure 1B) , and the protein levels of p16 INK4a and p53 were elevated in the senescent samples, whereas the pro-apoptotic protein Bid and the cell proliferation marker Ki-67 were decreased ( Figure 1C ). To identify unique genetic signatures differently expressed in senescent and young melanocytes, an unsupervised mRNA analysis was performed on samples from four donors. Hierarchical clustering indicated a good segregation between the young and senescent melanocyte cultures ( Figure 1D ). Furthermore, the first principal component showed clear segregation between the groups ( Figure 1E ).
In total, we identified 351 differentially expressed genes (fold change ≤À2 or ≥+2, P-value ≤ 0.01) when comparing young and senescent melanocytes. These genes included 139 upregulated and 212 downregulated genes in the senescent melanocytic samples compared with young melanocytic samples (Tables S1 and S2 ). Several of the altered genes were functionally linked to the senescent state. Downregulated genes were enriched with cell cycle-related GO terms, such as M phase, cell cycle, and cell cycle phase, whereas upregulated genes were enriched with the GO terms cell cycle arrest and intracellular signaling cascade (Table 1) . The list of differentially expressed genes was transformed into a set of relevant networks using Ingenuity Pathway Analysis (IPA). Nineteen associated networks were generated, of which the category 'Cancer, Endocrine System Disorders, Hematological Disease' scored second top (Table S3 ) and was considered of interest. This network showed TUBB3 as the most interconnected gene (Figure 2A ). The identification of potential upstream regulators revealed a strong activation of CDKN2A (encoding the p16 INK4a ) and TP53 and inhibition of TGFB1 and E2F among others in the senescence model system ( Figure 2B ). Interestingly, in this analysis, TUBB3 was regulated by TP53 and TGFB1. TUBB3 encodes the class 3 beta-tubulin (tubulin b-3) protein, which is specific for neuroectodermal-derived cell types, such as melanocytes. Considering the results presented in Figure 2A and B and the fact that tubulin b-3 suits the concept of a diagnostic marker of melanoma in the skin, as it is not expressed in keratinocytes, we selected TUBB3 as an interesting candidate gene for further studies. To verify the microarray analysis, tubulin b-3 was immunoblotted in four coupled samples of young and senescent melanocyte cultures, which revealed a Relationship between the senescent melanocyte model system and gene expression in nevi and melanoma To investigate whether the model system harbors information relevant for transformation of melanocytic nevi to melanomas, we compared the transcriptomes of young and senescent melanocytes to a previously published dataset consisting of 45 primary melanomas and 18 benign skin nevi (Talantov et al., 2005) using gene set enrichment analysis (GSEA). Six common hallmarks shared between young versus senescent melanocytes and melanomas versus benign nevi were identified. Specifically, E2F targets, mTORC1 signaling, and MYC targets were enriched in both young melanocytes and melanomas. In addition, four common hallmarks, including the p53 pathway, were enriched in both senescent melanocytes and nevi ( Figure S1 ). Thus, there are indications that genes found in the model system of senescence also play a role in benign nevi. We employed our a priori defined senescence sets of upand downregulated genes to determine whether they were randomly distributed throughout the ranked gene list of the clinical dataset and showed strong significant enrichment (P < 0.01) in nevi and melanomas, respectively ( Figure 3A , C). Thus, this model system is applicable to search for new markers to distinguish between nevi and melanomas. The leading edge subset of the senescent gene sets of up-and downregulated genes consisted of 26 and 58 genes, respectively ( Figure 3B , D). Among these 58 genes, TUBB3 was found, and as it also appeared as a hub in the IPA (Figure 2A ), it was selected for staining of melanocytic lesions.
Expression of tubulin b-3 in human melanocytic lesions To evaluate the possible clinical applicability of tubulin b-3 expression as a marker of melanocytes in a senescent state, we stained formalin-fixed paraffin-embedded samples of benign and malignant melanocytic lesions from patients (Table 2 ). In melanocytes, tubulin b-3 expression was detected in the cytoplasm, and its distribution was similar to Melan-A staining (compare Figure S2A and S2B). Intra-epidermal melanocytes and Figure 4A presents a gross overview of the lesion and the insets illustrate the staining appearance of the superficial and deep parts in detail. A similar staining pattern was observed in dysplastic nevi ( Figure 4B ). Melanoma in situ and thin primary melanomas (≤1 mm) stained strongly for tubulin b-3 ( Figure S2C , D). Thick melanomas (>1 mm) showed strong staining in both the superficial and deep parts ( Figure 4C ). Interestingly, three of five thick melanomas (>2.0 mm) exhibited variable staining in a disordered pattern with focal loss of tubulin b-3 ( Figure S2E ). Noteworthy, strong staining was noted in the invasive front of the tumor ( Figure S2E ). Image analysis of the staining intensities of the superficial and deep intradermal melanocytic components in both benign and dysplastic melanocytic nevi revealed significant loss of staining intensity in benign lesions, whereas no gradient was found in primary malignant melanomas ( Figure 4D -F). Given that melanomas in situ and thin primary melanomas (≤1 mm) lack the deep intradermal melanocytic component, they were not subjected to image analysis.
Depletion of tubulin b-3 prevents the migration of melanoma cells
To verify the impact of tubulin b-3 on cell growth and migration, tubulin b-3 was depleted in four young melanocytes and the melanoma cell lines WM115, WM793, WM278, and FM55P using siRNA, which reduced the protein expression (Figures 5A, B and S3) . Proliferation was estimated during a 24-h period. Cultures depleted of tubulin b-3 or pretreated with the tubulin destabilizing drugs colchicine and vinblastine exhibited significantly reduced proliferation ( Figure 5C , D). Cell cycle analysis revealed that upon depletion of tubulin b-3, the cells increasingly accumulated in the G2/M phase in both primary melanocytes and melanoma cell lines (Figures 5E, F and S4) . Similarly, the migration was reduced in cultures treated with tubulin inhibitors and after the depletion of tubulin b-3 ( Figure 5G , H). To determine if depletion of tubulin b-3 was accompanied by senescence like cell appearance, the activity of the senescent marker b-Gal was studied. As presented in Figure 6 (A, B), b-Gal activity was enhanced twofold and 3.7-fold in melanocytes and melanoma cells, respectively. The senescent state was further confirmed by augmented expression of p16 ( Figure 6C, D) . However, no increase in the number of apoptotic cells, as detected by DNA content in the cell cycle analysis ( Figure S4 ) and by analysis of nuclear morphology, could be found. In Table 1 . Gene ontology term analyses using DAVID presenting down-and upregulated genes in senescence melanocyte cultures as compared to young cultures (P < 0.05). 
Discussion
In our model system, growth-arrested melanocytes displayed several well-documented characteristics of senescence, including enlarged and flat morphology, b-Gal activity, and altered expression of p53, p16, and Ki-67. Moreover, we also detected protection against apoptotic cell death as the pro-apoptotic BH3-only protein Bid was downregulated in senescent cultures. Telomere shortening and the activation of oncogenes are among the central inducers of senescence (Kuilman et al., 2010; Serrano et al., 1997) . However, various stress conditions due to in vitro cultivation, such as production of reactive oxygen species (ROS) and growth factor starvation, might also induce a premature senescence state (Kuilman et al., 2010) . The gene expression profiles of our material indicated upregulation in the senescent versus young melanocytes of several manifested senescence markers (reviewed in Campisi and d'Adda di Fagagna, 2007) , including CDKN2A (encoding p16) and TP53, and the downregulation of MKI67 (encoding Ki-67), reflecting reduced proliferation. However, it was recently demonstrated that none of the above-mentioned proteins nor the established senescence markers PML and b-Gal could be used to distinguish nevi from melanomas (Tran et al., 2012) . Thus, gene expression profiles might identify novel candidate proteins for diagnostic use. Consistent with recent findings, we revealed that growth-promoting signaling pathways, such as E2F targets (Park et al., 2006) , mTORC1 signaling (Damsky et al., 2015) , and MYC targets (Leikam et al., 2014) , are enriched in both young melanocytes and melanomas. Furthermore, a concordant gene expression difference as derived from the senescence model system is found between melanomas and nevi. The contributing markers are, thus, possible candidate markers to distinguish between benign and malignant melanocytic lesions. The neuron-specific subtype of b-tubulin encoded by TUBB3 was identified among the leading edge subset of the upregulated genes in young melanocytes and melanoma. According to the IPA of highly interconnected networks annotated as related to cancer, TUBB3 was identified as the most connected gene and was therefore selected to study in melanocytic lesions. Melanocytic lesion analysis revealed a tubulin b-3 staining gradient in the intradermal component of benign and dysplastic melanocytic lesions, and this was not observed in melanomas. The results suggest that analysis of the tubulin b-3 staining pattern in the intradermal melanocytic component might have diagnostic impact and should be further verified. In previous investigations of clinical material, tubulin b-3 expression was associated with the ascending histological grade of the malignancy (Kavallaris, 2010) . Patients with non-small-cell lung cancer showed survival advantages if the tumor was negative for tubulin b-3 (Levallet et al., 2012) . In contrast, loss of tubulin b-3 expression was related with poor prognosis in acral lentiginous melanoma (Akasaka et al., 2009 ). However, this type of melanoma is rare in Caucasians and was not present in our material. A recent publication by Shimizu et al. (2016) also suggests that decreased expression of tubulin b-3 is associated with unfavorable prognosis in melanoma, but the tumor type was not specified. According to the results presented in Figure 3 , a few tumors show gene expression similar to that of nevi, indicating the heterogenety of melanomas. However, it Figure 3 . Senescence-associated gene set enrichment analysis in the combined datasets of the cell culture model and a public dataset of nevi and melanomas. Human melanocytes from four donors were cultured for 3 days (young) and until they stopped dividing and displayed senescent morphology (minimum of 30 days). Gene expression was analyzed by microarrays and compared with a public gene set of 45 primary melanomas and 18 benign skin nevi (Talantov et al., 2005) utilizing the GSEA of up-and downregulated gene sets in senescence with respect to the ranked expression of the public dataset. (A) Enrichment plot of upregulated genes in senescent versus young melanocytes. Normalized enrichment score = 1.62, nominal P-value < 0.002, FDR q-value < 0.002. (B) Heat map displaying the GSEA leading edge upregulated genes that exhibited increased expression in nevi versus melanomas. (C) Enrichment plot of downregulated genes in senescent versus young melanocytes. Normalized enrichment score = 2.03, nominal P-value < 0.001, FDR q-value < 0.001. (D) Heat map displaying the GSEA leading edge downregulated genes that exhibited increased expression in melanoma versus nevi. The rows in the heat maps show the genes, and the columns show each individual sample. The scale bar shows the color-coded differential expression, whereas the range of colors shows the range of expression values (high, red; low, blue). In anticancer treatment, tubulins are targeted with vinca alkaloids and taxanes, and tubulin b-3 expression is associated with resistance to the above-mentioned drugs in a wide range of tumor types (Kavallaris, 2010) . In cell culture experiments, tubulin b-3 protein expression correlated with resistance to paclitaxel in malignant melanoma cell lines (Akasaka et al., 2009 ). Tubulins constitute microtubules, which are essential for cell division including segregation of the chromosomes during mitosis (Vicente and Wordeman, 2015) . Accordingly, we found growth arrest and G2/M phase accumulation in tubulin b-3-depleted cells. Previously oxidative stress-induced senescence also shows G2/M phase accumulation (Chen et al., 2000) . Thus, we demonstrate that depletion of tubulin b-3 leads to a senescence state, specified by the markers p16 and b-Gal and also manifested as reduced proliferation and migration. Our results are in concordance with previous findings that B16/F10 melanoma cells exposed to the microtubule toxin JG-03-14 exhibited senescence characteristics after treatment (Biggers et al., 2013) .
In conclusion, we developed a melanocytic senescence model system to identify genes that impact cellular proliferative activity. The combination of microarray analyses from the cell culture model and clinical samples revealed novel biomarkers that could define senescencerelated processes and improve the diagnostic accuracy of melanocytic lesions. Histopathological evaluation of tubulin b-3 as a biomarker suggested that the staining intensity in the deep intradermal component might offer guidance in diagnosing melanocytic lesions.
Methods Cell culture and conditions
Melanocytes were obtained from Caucasian donors (0-3 yr of age) by means of foreskin circumcisions, and pure cultures were established as previously described (Andersson et al., 2001) . All experiments were performed according to the ethical principles of the Helsinki Declaration and were approved by the Ethical Review Board in Link€ oping, Sweden. The melanocytes were cultured in Medium 199 with supplements and incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. The experiments were conducted between passages 2 and 10. The first sample (young) was obtained 3 days after isolation/seeding, and the second sample (senescent) was isolated after a minimum of 30 days when the cells exhibited senescent-like morphology, that is, flattened and non-proliferative.
Four primary melanoma cell lines were used: WM115, WM793, WM278, and FM55P (provided by Prof Meenhard Herlyn, Wistar Institute, Philadelphia, PA, USA). The melanoma cells were cultivated in DMEM supplemented with 10% fetal bovine serum, 2 mM Lglutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin. The microtubule-destabilizing drugs vinblastine (100 nM, 24 h, stock in DMSO) and colchicine (10 lM, 30 min, stock in DMSO) were used prior to experiments when indicated. Controls for DMSO showed no interference with the experiments.
b-Galactosidase assays b-Gal staining was performed as described before (Dimri et al., 1995) . Images were captured using an Olympus BX51 Microscope (Olympus, Tokyo, Japan). For b-Gal activity, cells were lysed in 250 mM Tris, 0.1% Triton X-100, and 1 mM Pefabloc supplemented with 4-MU b-D-galactopyranoside diluted in 0.2 M sodium citrate buffer, pH 4.5. The lysate was incubated for 40 min at 37°C in the dark before stop solution of 1 M glycine-NaOH buffer was added, and the fluorescence was analyzed (k ex 355/k em 460 nm). The activity was correlated to the total amount of protein. Thickness represents the measurement of the nevus/malignant melanoma cells from the granular cell layer to the deepest extension of the lesion. The anatomic level refers to the deepest extension of the nevus/ malignant melanoma into the papillary dermis, reticular dermis, and subcutaneous tissue. Whole human genome microarray analysis
Microarray analysis was performed on melanocytes from four different donors. After isolation of total RNA (TRIzol; Sigma, St Louis, MO, USA), the quality was controlled using an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Labeling and hybridization were performed using the Affymetrix Human Genome Microarray (WT GeneTitan ST1.1; Plate type, HuGene-1_1-st-v1-16; Array type, HuGene-1_1-st-v1) according to the manufacturer's protocols (Affymetrix Inc., Santa Clara, CA, USA) at the Bioinformatics and Expression Analysis Core Facility (Karolinska Institute, Stockholm, Sweden). The raw.CEL files generated from this analysis were processed using the AGILENT GENESPRING GX 13 software package (Agilent Technologies, Santa Clara, CA, USA). The exon-level data were summarized using the RMA16 algorithm (Bolstad et al., 2003) , and the baseline was transformed to the median of all samples. Entities are filtered based on their signal intensity values between the 20th and 100th percentiles in at least one sample. The cutoff fold change was AE2 (P < 0.01). The data were quality-assessed before and after normalization through the inspection of hierarchical clustering trees and principal component analysis (PCA) plots. For the gene-level experiment, the data were normalized using a quantile algorithm (Bolstad et al., 2003) , and the baseline was transformed to the median of all samples. The data have been deposited in the Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo/) accession number GSE83922. The gene id conversion was performed by converting the EntrezGene IDs to official gene symbols.
Gene ontology and network analysis
Gene ontology term analyses using gene symbols were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov) (Huang et al., 2009a,b) . IPA software (Ingenuity Systems, http://www.ingenuity.com/) was used to generate the networks of direct relationships between molecules and for upstream regulator analysis.
Gene set enrichment analysis GSE3189 identifier was used to import microarray data from a public dataset (Talantov et al., 2005) previously analyzed on an Affymetrix
Hu133A microarray containing 22 000 probe sets into the AGILENT GENESPRING GX 13 software package. In this study, the majority of the primary melanomas had a thickness of <4 mm and the majority of nevi represented compound and intradermal nevi. GSEA was used to identify common hallmarks of the experimental system (young versus senescent melanocytes) and the public dataset (melanoma versus nevi) (Talantov et al., 2005) and to compare derived senescence-associated gene sets to the entire ranked gene list from the dataset (Subramanian et al., 2005) . The results with P-values ≤ 0.05 and false discovery rates ≤0.25 were considered significant.
Western blot and dot blot analysis
Melanocyte cell cultures were prepared for immunoblot as previously described (Appelqvist et al., 2011) . Immunodetection was performed with monoclonal mouse antibodies against p16 and p53 (both from Santa Cruz), a monoclonal rabbit antibody against tubulin b-3 (Novus Biologicals, Littletown, CO, USA) and polyclonal rabbit antibodies against Bid (BD Pharmingen, San Jose, CA, USA) and Ki-67 (Abcam, Cambridge, UK) followed by the corresponding horseradish peroxidase (DAKO, Solna, Sweden)-conjugated secondary antibody. The membranes were reprobed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Biogenesis, Poole, UK) as an internal control. Densitometric quantification of the bands was performed using IMAGE LAB software (Version 4.1; Bio-Rad, Watford, UK).
Tubulin b-3 silencing siRNA transfection against tubulin b-3 was performed using 5 nM TUBB3 siRNA (SI02636655, SI02780883; Qiagen, Germantown, MD, USA) and 6 ll HiPerFect Transfection Reagent for 24 h. Optimal transfection conditions for the cells were determined by titration using Alexa Fluor 555-labeled non-silencing siRNA with a scrambled sequence without homology to mammalian genes (AATTCTCC-GAACGTGTCACGT, Qiagen). This siRNA was used as negative control, and siRNA targeting Lamin A/C (SI03650332, Qiagen) served as positive control, as recommended by the manufacturer.
Cell migration and proliferation
To determine migration, the Cultrex â 96-well Migration Assay was used (Trevigen Inc., Gaithersburg, MD, USA). The top invasion were grown in the top chamber, and the migrated cells were dissociated and incubated with Calcein-AM; the assay chamber was analyzed using a VICTOR X3 multiple counter (k ex 485/k em 520 nm; PerkinElmer, Waltham, MA, USA). Reproducibility was confirmed by internal reference (four individual cell lines, each value is mean of three replicates). Proliferation was assessed in cultures 24 h after seeding using the WST-1 cell proliferation reagent (1:10; Roche Diagnostics GmbH, Mannheim, Germany). Absorbance was measured at 450 and 650 nm to determine proliferation and background absorbance from the medium using VICTOR X3. Nuclear morphology was evaluated in fixed cells stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Thermo Fischer, Paisley, UK). Nuclear morphology was assessed in minimums of 200 nuclei in each sample.
Melanocytic lesions
The study included five benign melanocytic nevi, five dysplastic melanocytic nevi, five melanomas in situ, five primary malignant melanomas stadium pT1a, and five primary malignant melanomas stadium pT2a-pT4a, as presented in Table 2 (Ethical permission; Dnr 2013-31431). Clinical data were not available. The slides were stained with hematoxylin and eosin and blinded for diagnostic re-evaluation of tumor type, thickness, Clark level, and presence of ulceration by an experienced pathologist. The grade of sun-induced damage and skin structure were evaluated to identify eventual facial and acral lesions.
Immunohistochemistry and image analysis
Serial sections (5 lm) of formalin-fixed paraffin-embedded tissue were processed for routine immunohistochemistry. Antibody staining was performed with anti-tubulin b-3 (1:100), Melan-A (Dako; 1:50), and Ki-67 (1:500). Samples were incubated with a polymer linked to alkaline phosphatase (MACH2) and were visualized using Vulcan Fast Red (both from Histolab, G€ oteborg, Sweden). The slides were blinded and the staining intensity and staining pattern of tubulin b-3 was determined by K Lundmark and K Orfanidis independently. The slides were also scanned using an APERIO SCANNER and viewed on the IMAGESCOPE software (Leica, Wetzlar, Germany), and image analysis of staining intensities was performed on blinded images. The same number of melanocytic areas (300 9 200 lm) from the superficial and deep intradermal part of each lesion (of similar melanocytic content in paired selections) was randomly selected, and the staining intensities were determined using the color deconvolution algorithm (Ruifrok and Johnston, 2001; Ruifrok et al., 2003) on magnified (400x) images using the IMAGEJ program (http:// imagej.nih.gov/ij/). From luminosity histograms, the red chromophore density was calculated using the slightly modified formula, P
Area ðpixels 2 Þ , as previously described (Amber, 2015; Billings et al., 2015) . Lesions with no or only superficial intradermal melanocytic component were excluded from this analysis.
Cell cycle analysis
Cell cycle distribution was assayed as described by Vindel€ ov et al. (Vindel€ ov et al., 1983) . After washing in PBS, the cells were trypsinated, pelleted, and resuspended in citrate buffer (250 mM sucrose, 40 mM trisodium citrate dihydrate, and 5% DMSO, pH 7.6). Nuclei were isolated after digestion in 0.03% trypsin. Finally, cells were stained with 0.37 mM propidium iodide and 2 mM spermine tetrahydrochloride and subjected to flow cytometry (Gallios flow cytometer;
Beckman Coulter Inc., Fullerton, CA, USA). In each experiment, data from 5000 cells were obtained and the histograms of DNA content were analyzed using the KALUZA software (Beckman Coulter Inc.).
Statistical analysis
Microarray data were evaluated with unpaired t test and corrected for multiple testing using the Benjamini-Hochberg method (Huang et al., 2009a) . Differentially expressed genes with a fold change ≥AE2 and Pvalue ≤ 0.01 were included in further analyses. GSEA used a permutation test procedure to evaluate the significance of enrichments; P ≤ 0.05 and false discovery rate ≤0.25 were used as the thresholds. Fisher's exact test, as implemented in IPA and other pathway analysis applications, was used to assess the significance of the association between a pathway and the differentially expressed genes. The image analyses of the staining intensities of histological specimens were compared using Student's t test for independent samples. One-way ANOVA and Dunnett post hoc analyses were used for multiple comparisons between groups in the tubulin b-3 inhibition studies. 
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